UNICHEMLAB — Unichem Laboratories Balance Sheet
0.000.00%
- IN₹35.63bn
- IN₹39.06bn
- IN₹21.11bn
- 29
- 39
- 38
- 24
Annual balance sheet for Unichem Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | R2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3,171 | 3,761 | 1,854 | 1,582 | 1,167 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,007 | 6,460 | 7,487 | 8,184 | 8,965 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 13,773 | 16,449 | 15,885 | 17,433 | 20,295 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 14,464 | 14,823 | 14,026 | 13,172 | 13,100 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 31,257 | 33,188 | 31,930 | 32,750 | 35,694 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5,058 | 5,521 | 6,396 | 7,376 | 9,920 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 5,689 | 7,004 | 7,577 | 8,367 | 11,188 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 25,568 | 26,184 | 24,353 | 24,383 | 24,506 |
Total Liabilities & Shareholders' Equity | 31,257 | 33,188 | 31,930 | 32,750 | 35,694 |
Total Common Shares Outstanding |